Maze Therapeutics CSBO exercises 14,305 stock options
Maze Therapeutics, Inc. Chief Business and Strategy Officer Atul Dandekar exercised stock options to acquire a total of 14,305 shares of Common Stock on May 4, 2026.
Rhea-AI Filing Summary
Maze Therapeutics, Inc. Chief Business and Strategy Officer Atul Dandekar exercised stock options to acquire a total of 14,305 shares of Common Stock on May 4, 2026. The options were exercised at an exercise price of $10.42 per share.
Following these transactions, Dandekar directly holds 24,808 shares of Common Stock. The exercised options relate to awards that vest monthly over 48 months, with one award noted as having become fully vested on February 1, 2026, subject to continued service conditions described in the award agreements.
Positive
- None.
Negative
- None.
Insider Trade Summary
14,305 shares exercised/converted
Exercise
4 txns
Insider
Dandekar Atul
Role
CSBO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 8,320 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 5,985 | $0.00 | $0.00 |
| Exercise | Common Stock | 8,320 | $10.42 | $87K |
| Exercise | Common Stock | 5,985 | $10.42 | $62K |
Holdings After Transaction:
Stock Option (Right to Buy) — 47,929 contracts (Direct);
Common Stock — 24,808 shares (Direct)
Footnotes (2)
- F1. The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on February 1, 2026.
- F2. The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on April 1, 2023, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
Key Figures
Options exercised (total shares): 14,305 shares
Exercise price: $10.42 per share
Shares acquired from first option: 5,985 shares
+4 more
7 metrics
Options exercised (total shares)
14,305 shares
Stock options converted to Common Stock on May 4, 2026
Exercise price
$10.42 per share
Conversion or exercise price of the stock options
Shares acquired from first option
5,985 shares
Common Stock received from one option exercise on May 4, 2026
Shares acquired from second option
8,320 shares
Common Stock received from second option exercise on May 4, 2026
Common shares held after transactions
24,808 shares
Directly owned Maze Therapeutics Common Stock post-transaction
Option vesting schedule
1/48th monthly
One award vests monthly starting April 1, 2023, over 48 months
Fully vested date for one award
February 1, 2026
Date one option award became fully vested under award agreement
Key Terms
Stock Option (Right to Buy), Exercise or conversion of derivative security, vesting, award agreement, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)" for derivative entries"
Exercise or conversion of derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security""
vesting financial
"The option vested or vests as to 1/48th of the total award monthly"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
award agreement financial
"Pursuant to the terms of the reporting person's award agreement with the Issuer"
An award agreement is a legal contract that spells out the terms of a pay or equity grant—such as stock options, restricted shares, or cash bonuses—given to an employee, director or consultant. It describes what is being granted, any conditions for keeping it (for example, earning it over time or meeting performance targets), and what happens if the person leaves or breaks rules. Investors care because these agreements affect company costs, potential share dilution and how executives are motivated and rewarded.
continued service financial
"subject to the reporting person's continued service to the Issuer on each vesting date"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Maze Therapeutics (MAZE) CSBO Atul Dandekar report in this Form 4?
Atul Dandekar reported exercising stock options to acquire 14,305 shares of Maze Therapeutics Common Stock. These were compensation-related option exercises, not open-market purchases, and increased his directly held Common Stock position as reflected in the post-transaction holdings data.
What was the exercise price for Atul Dandekar’s Maze Therapeutics (MAZE) stock options?
The exercised Maze Therapeutics stock options had an exercise price of $10.42 per share. This price is disclosed as the conversion or exercise price for the derivative securities that were converted into Common Stock in the reported transactions.
How many Maze Therapeutics (MAZE) stock options did Atul Dandekar exercise on May 4, 2026?
On May 4, 2026, Atul Dandekar exercised options covering 14,305 underlying shares of Maze Therapeutics Common Stock. This total consists of two separate option exercises for 5,985 shares and 8,320 shares, both reported with transaction code M for derivative exercises.
How do the vesting terms of Atul Dandekar’s Maze Therapeutics (MAZE) options work?
One option award became fully vested on February 1, 2026, under his award agreement. Another vests in 48 equal monthly installments, with the first 1/48th vesting on April 1, 2023 and subsequent tranches vesting monthly, subject to his continued service to Maze Therapeutics.
Were Atul Dandekar’s Maze Therapeutics (MAZE) transactions open-market buys or option exercises?
The transactions were option exercises, not open-market purchases. They are coded M for “Exercise or conversion of derivative security,” indicating stock options were converted into Common Stock at a preset exercise price rather than bought on the open market.
AI-generated analysis. How Rhea-AI works. Not financial advice.
